U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc ...
- U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.
Merck’s blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer. In an older mid-stage trial testing patients whose cancer had spread even after treatment with at least one therapy, 24% of patients treated with Peloton’s drug showed an at least 30% shrinkage of targeted lesions.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Merck to buy cancer drug developer Peloton for $1.05 billion in cashMerck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 b...
Lire la suite »
Merck's Keytruda fails as monotherapy in breast cancer studyMerck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to mee...
Lire la suite »
Supreme Court gives Merck another shot to avoid Fosamax lawsuitsThe U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid laws...
Lire la suite »
Pharma giant Merck just struck a $1 billion deal for a drugmaker working on a new treatment for kidney cancerMerck is acquiring Peloton Therapeutics for $1 billion in cash to gain access to a treatment the company is developing for kidney cancer.
Lire la suite »
U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drugSupreme Court rules for Merck on claims it failed to warn about fracture risk from osteoporosis drug Fosamax
Lire la suite »
Supreme Court blocks bid to sue Merck over Fosamax bone fracturesSupreme Court unanimously blocks, for now, a class-action lawsuit against pharmaceutical giant Merck over 'atypical femoral fractures' caused by osteoporosis drug Fosamax.
Lire la suite »
Merck to buy cancer drug developer Peloton for $1.05 billion in cashMerck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 b...
Lire la suite »
Pharma giant Merck just struck a $1 billion deal for a drugmaker working on a new treatment for kidney cancerMerck is acquiring Peloton Therapeutics for $1 billion in cash to gain access to a treatment the company is developing for kidney cancer.
Lire la suite »
Merck's Keytruda fails as monotherapy in breast cancer studyMerck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to mee...
Lire la suite »
Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800A Japanese government panel approved Novartis' cancer treatment Kymriah at ...
Lire la suite »
‘This terrible disease’: Ovarian cancer is deadly, but new tests, treatments start to emergeCompared with other cancer success stories, the disease historically has had a shortage of good news. Until recently, it hasn’t benefited from new treatments for decades.
Lire la suite »